PMV Pharma’s Phase 2 trial shows 33% response in TP53 Y220C-mutated tumors, with ovarian cancer achieving a 43% response rate in interim results.
Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types
Where Today's News Shapes Tomorrow
